The New England Journal of Medicine | Research & Review Articles …
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Management of Insomnia | New England Journal of Medicine
Jul 17, 2024 · Insomnia is common and frequently occurs with other disorders. First-line cognitive behavioral therapy with or without medication can produce rapid, sustained alleviation of insomnia symptoms.
Hydrocortisone in Severe Community-Acquired Pneumonia | New …
Mar 21, 2023 · New perspectives on community-acquired pneumonia in 388 406 patients: results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009;64:1062-1069. Crossref
CD19 CAR T-Cell Therapy in Autoimmune Disease - The New …
Feb 21, 2024 · Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term immune suppression. Resetting aberran...
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH …
Feb 7, 2024 · From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National ...
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell …
Sep 13, 2024 · Durvalumab is a selective, high-affinity human IgG1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1), blocking its interaction with programmed death 1 (PD-1) and CD80 on ...
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Dec 10, 2020 · In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart ...
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without ...
Jun 14, 2024 · Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of ...
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after ...
Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis
Sep 14, 2022 · A total of 249 patients were included in the interim analysis. The trial was halted owing to between-group differences in the safety outcomes without a significant difference in the incidence of ...